News

Wearable Cognixion ONE Axon named FDA breakthrough device

Cognixion’s flagship device Cognixion ONE Axon, a product designed to improve communication in people with severe motor impairments, has beed granted breakthrough device designation by the U.S. Food and Drug Administration (FDA). The wireless device is specifically designed for people with people with amyotrophic lateral sclerosis (ALS)…

First ALS patient dosed in Cellenkos’ trial of CK0803

Cellenkos has dosed the first patient in the Phase 1/1b clinical trial that’s evaluating its regulatory T-cell-based therapy CK0803 for the treatment of amyotrophic lateral sclerosis (ALS). The patient will be one of six participants included in the Phase 1 run-in period of the REGALS clinical trial…

US Senate ALS Caucus to advocate for policies, research

The bipartisan Senate ALS Caucus has been reestablished to heighten awareness of the needs of those living with amyotrophic lateral sclerosis (ALS), advance policies, improve patient support, and advocate for research investments. U.S. Sens. Chris Coons, D-Delaware, and Mike Braun, R-Indiana, reintroduced the caucus, which is now expanded with…